{"preliminary_commentary":{"by_channel":{"x_thread":4,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06179160","nct_id":"NCT06179160","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06179160. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"INCB161734 at the protocol-defined dose strength based on cohort assignment.","label":"Part 1a: Dose Escalation monotherapy","type":"EXPERIMENTAL"},{"description":"INCB161734 at the protocol-defined dose strength based on cohort assignment.","label":"Part 1b: Dose Expansion monotherapy","type":"EXPERIMENTAL"},{"description":"INCB161734 at the protocol-defined dose strength based on cohort assignment.","label":"Part 1c: Pharmacodynamic cohort","type":"EXPERIMENTAL"},{"description":"INCB161734 in combination at the protocol-defined dose strength based on cohort assignment.","label":"Part 2a: Dose Escalation combination","type":"EXPERIMENTAL"},{"description":"INCB161734 in combination at the protocol-defined dose strength based on cohort assignment.","label":"Part 2b: Dose Expansion combination","type":"EXPERIMENTAL"},{"description":"Evaluate food effect on drug exposure as defined in the protocol.","label":"Part 1d: Food-Effect","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-01-01","type":"ESTIMATED"},"conditions":["Solid Tumors"],"enrollment":{"count":710,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"INCB161734","otherNames":[],"type":"DRUG"},{"name":"Cetuximab","otherNames":[],"type":"DRUG"},{"name":"Retifanlimab","otherNames":[],"type":"DRUG"},{"name":"GEMNabP","otherNames":[],"type":"DRUG"},{"name":"mFOLFIRINOX","otherNames":[],"type":"DRUG"},{"name":"FOLFOX","otherNames":[],"type":"DRUG"},{"name":"FOLFIRI","otherNames":[],"type":"DRUG"},{"name":"INCA33890","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-22","lead_sponsor":"Incyte Corporation","official_title":"A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-01-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of participants with Dose Limiting Toxicities (DLTs)","timeFrame":"Up to 28 days"},{"measure":"Number of participants with Treatment-emergent Adverse Events (TEAEs)","timeFrame":"Up to 2 years and 90 days"},{"measure":"Number of participants with TEAEs leading to dose modification or discontinuation","timeFrame":"Up to 2 years and 90 days"}],"references":[],"start_date":{"date":"2024-01-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","url":"https://clinicaltrials.gov/study/NCT06179160"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06179160"}